NICE set to recommend Boehringer's type 2 diabetes drug Jardiance

22 January 2015

England’s health care costs watchdog the National Institute for Health and Care Excellence (NICE) has issued further draftguidance which recommends Jardiance (empagliflozin), marketed by German family-owned pharma major Boehringer Ingelheim, for treating type 2 diabetes.

In a preliminary appraisal last summer, NICE called for the company to provide more evidence to demonstrate that empagliflozin is a good use of NHS resources when compared with other treatments that are already available. Boehringer Ingelheim responded and submitted a new cost-effectiveness model which showed that empagliflozin combination therapy is a cost effective treatment option for some people with type 2 diabetes.

Commenting on the draft guidance, Carole Longson, director of the NICE Centre for Health Technology Evaluation, said: “We are pleased that Boehringer Ingelheim responded to our consultation and provided new evidence to allow us to recommend empagliflozin as a treatment option for some people with type 2 diabetes.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK